<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:00:42Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4832389" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4832389</identifier><datestamp>2016-04-20</datestamp><setSpec>blackwellopen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Hum Mutat</journal-id>
      <journal-id journal-id-type="iso-abbrev">Hum. Mutat</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1098-1004</journal-id>
      <journal-id journal-id-type="publisher-id">HUMU</journal-id>
      <journal-title-group>
        <journal-title>Human Mutation</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1059-7794</issn>
      <issn pub-type="epub">1098-1004</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4832389</article-id>
      <article-id pub-id-type="pmcid">PMC4832389</article-id>
      <article-id pub-id-type="pmc-uid">4832389</article-id>
      <article-id pub-id-type="pmid">26694085</article-id>
      <article-id pub-id-type="doi">10.1002/humu.22946</article-id>
      <article-id pub-id-type="publisher-id">HUMU22946</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Weaver SyndromeâAssociated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro</article-title>
      </title-group>
      <contrib-group>
        <contrib id="humu22946-cr-0001" contrib-type="author" corresp="yes">
          <name>
            <surname>Cohen</surname>
            <given-names>Ana S.A.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="author-note" rid="humu22946-note-0001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0002" contrib-type="author">
          <name>
            <surname>Yap</surname>
            <given-names>Damian B.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0003">
<sup>3</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0004">
<sup>4</sup>
</xref>
          <xref ref-type="author-note" rid="humu22946-note-0001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0003" contrib-type="author">
          <name>
            <surname>Lewis</surname>
            <given-names>M.E. Suzanne</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0004" contrib-type="author">
          <name>
            <surname>Chijiwa</surname>
            <given-names>Chieko</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0005" contrib-type="author">
          <name>
            <surname>RamosâArroyo</surname>
            <given-names>Maria A.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0006" contrib-type="author">
          <name>
            <surname>Tkachenko</surname>
            <given-names>NatÃ¡lia</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0007" contrib-type="author">
          <name>
            <surname>Milano</surname>
            <given-names>Valentina</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0008">
<sup>8</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0008" contrib-type="author">
          <name>
            <surname>Fradin</surname>
            <given-names>MÃ©lanie</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0009">
<sup>9</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0009" contrib-type="author">
          <name>
            <surname>McKinnon</surname>
            <given-names>Margaret L.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0010" contrib-type="author">
          <name>
            <surname>Townsend</surname>
            <given-names>Katelin N.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0011" contrib-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>Jieqing</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0012" contrib-type="author">
          <name>
            <surname>Van Allen</surname>
            <given-names>M.I.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0013" contrib-type="author">
          <name>
            <surname>Ross</surname>
            <given-names>Colin J.D.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0010">
<sup>10</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0014" contrib-type="author">
          <name>
            <surname>Dobyns</surname>
            <given-names>William B.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0011">
<sup>11</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0012">
<sup>12</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0013">
<sup>13</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0015" contrib-type="author">
          <name>
            <surname>Weaver</surname>
            <given-names>David D.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0014">
<sup>14</sup>
</xref>
        </contrib>
        <contrib id="humu22946-cr-0016" contrib-type="author">
          <name>
            <surname>Gibson</surname>
            <given-names>William T.</given-names>
          </name>
          <xref ref-type="aff" rid="humu22946-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="humu22946-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="humu22946-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Medical Genetics</named-content>
        <institution>University of British Columbia</institution>
        <named-content content-type="city">Vancouver</named-content>
        <named-content content-type="country-part">British Columbia</named-content>
        <named-content content-type="post-code">V6T 1Z3</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="humu22946-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <institution>Child and Family Research Institute</institution>
        <named-content content-type="city">Vancouver</named-content>
        <named-content content-type="country-part">British Columbia</named-content>
        <named-content content-type="post-code">V5Z 4H4</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="humu22946-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pathology and Laboratory Medicine</named-content>
        <institution>University of British Columbia</institution>
        <named-content content-type="city">Vancouver</named-content>
        <named-content content-type="country-part">British Columbia</named-content>
        <named-content content-type="post-code">V6T 2B5</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="humu22946-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of Molecular Oncology</named-content>
        <institution>British Columbia Cancer Research Centre</institution>
        <named-content content-type="city">Vancouver</named-content>
        <named-content content-type="country-part">British Columbia</named-content>
        <named-content content-type="post-code">V5Z 1L3</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="humu22946-aff-0005">
        <label>
          <sup>5</sup>
        </label>
        <institution>Children's and Women's Health Centre of British Columbia</institution>
        <named-content content-type="city">Vancouver</named-content>
        <named-content content-type="country-part">British Columbia</named-content>
        <named-content content-type="post-code">V6H 3N1</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="humu22946-aff-0006">
        <label>
          <sup>6</sup>
        </label>
        <named-content content-type="organisation-division">Department of Medical Genetics, Complejo Hospitalario de Navarra, IdiSNA</named-content>
        <institution>Navarra Institute for Health Research</institution>
        <named-content content-type="city">Pamplona</named-content>
        <named-content content-type="post-code">31008</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="humu22946-aff-0007">
        <label>
          <sup>7</sup>
        </label>
        <named-content content-type="organisation-division">Medical Genetics Service, Medical Genetics Center Dr. Jacinto MagalhÃ£es</named-content>
        <institution>Porto Hospital Center</institution>
        <named-content content-type="city">EPE</named-content>
        <named-content content-type="country-part">Porto</named-content>
        <named-content content-type="post-code">4099â001</named-content>
        <country country="PT">Portugal</country>
      </aff>
      <aff id="humu22946-aff-0008">
        <label>
          <sup>8</sup>
        </label>
        <named-content content-type="organisation-division">Instituto di Genetica Medica, UniversitÃ  Cattolica del Sacro Cuore</named-content>
        <institution>Policlinico Universitario Agostino Gemelli</institution>
        <named-content content-type="city">Roma</named-content>
        <named-content content-type="post-code">00168</named-content>
        <country country="IT">Italy</country>
      </aff>
      <aff id="humu22946-aff-0009">
        <label>
          <sup>9</sup>
        </label>
        <named-content content-type="organisation-division">Service de GÃ©nÃ©tique Clinique</named-content>
        <institution>Centre de RÃ©fÃ©rence Anomalies du DÃ©veloppement</institution>
        <named-content content-type="city">CHU Rennes</named-content>
        <named-content content-type="country-part">Rennes</named-content>
        <named-content content-type="post-code">35203</named-content>
        <country country="FR">France</country>
      </aff>
      <aff id="humu22946-aff-0010">
        <label>
          <sup>10</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pediatrics, Division of Translation Therapeutics</named-content>
        <institution>University of British Columbia</institution>
        <named-content content-type="city">Vancouver</named-content>
        <named-content content-type="country-part">British Columbia</named-content>
        <named-content content-type="post-code">V6H 3V4</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="humu22946-aff-0011">
        <label>
          <sup>11</sup>
        </label>
        <named-content content-type="organisation-division">Center for Integrative Brain Research</named-content>
        <institution>Seattle Children's Hospital</institution>
        <named-content content-type="city">Seattle</named-content>
        <named-content content-type="country-part">Washington</named-content>
        <named-content content-type="post-code">98101</named-content>
      </aff>
      <aff id="humu22946-aff-0012">
        <label>
          <sup>12</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pediatrics</named-content>
        <institution>University of Washington</institution>
        <named-content content-type="city">Seattle</named-content>
        <named-content content-type="country-part">Washington</named-content>
        <named-content content-type="post-code">98195</named-content>
      </aff>
      <aff id="humu22946-aff-0013">
        <label>
          <sup>13</sup>
        </label>
        <named-content content-type="organisation-division">Department of Neurology</named-content>
        <institution>University of Washington</institution>
        <named-content content-type="city">Seattle</named-content>
        <named-content content-type="country-part">Washington</named-content>
        <named-content content-type="post-code">98105</named-content>
      </aff>
      <aff id="humu22946-aff-0014">
        <label>
          <sup>14</sup>
        </label>
        <named-content content-type="organisation-division">Department of Medical and Molecular Genetics</named-content>
        <institution>Indiana University School of Medicine</institution>
        <named-content content-type="city">Indianapolis</named-content>
        <named-content content-type="country-part">Indiana</named-content>
        <named-content content-type="post-code">46202â5251</named-content>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>Correspondence to: Ana S.A. Cohen, Child &amp; Family Research Institute, 950 West 28<sup>th</sup> Avenue, A4â151 Bay 17, Vancouver, British Columbia V5Z 4H4, Canada. Eâmail: <email>acohen@cfri.ca</email></corresp>
        <fn id="humu22946-note-0001">
          <label>â </label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <volume>37</volume>
      <issue>3</issue>
      <issue-id pub-id-type="doi">10.1002/humu.2016.37.issue-3</issue-id>
      <fpage>301</fpage>
      <lpage>307</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>12</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 Wiley Periodicals, Inc. <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2015 The Authors. <sup>**</sup><italic>Human Mutation</italic> published by Wiley Periodicals, Inc.</copyright-statement>
        <license license-type="creativeCommonsBy-nc-nd">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons AttributionâNonCommercialâNoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is nonâcommercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:HUMU-37-301.pdf"/>
      <abstract>
        <title>ABSTRACT</title>
        <p>Weaver syndrome (WS) is a rare congenital disorder characterized by generalized overgrowth, macrocephaly, specific facial features, accelerated bone age, intellectual disability, and susceptibility to cancers. <italic>De novo</italic> mutations in the enhancer of zeste homolog 2 (<italic>EZH2)</italic> have been shown to cause WS. EZH2 is a histone methyltransferase that acts as the catalytic agent of the polycombârepressive complex 2 (PRC2) to maintain gene repression via methylation of lysine 27 on histone H3 (H3K27). Functional studies investigating histone methyltransferase activity of mutant EZH2 from various cancers have been reported, whereas WSâassociated mutations remain poorly characterized. To investigate the role of EZH2 in WS, we performed functional studies using artificially assembled PRC2 complexes containing mutagenized human EZH2 that reflected the codon changes predicted from patients with WS. We found that WSâassociated amino acid alterations reduce the histone methyltransferase function of EZH2 in this <italic>in vitro</italic> assay. Our results support the hypothesis that WS is caused by constitutional mutations in <italic>EZH2</italic> that alter the histone methyltransferase function of PRC2. However, histone methyltransferase activities of different EZH2 variants do not appear to correlate directly with the phenotypic variability between WS patients and individuals with a common c.553G&gt;C (p.Asp185His) polymorphism in <italic>EZH2</italic>.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="humu22946-kwd-0001">EZH2</kwd>
        <kwd id="humu22946-kwd-0002">histone methyltransferase</kwd>
        <kwd id="humu22946-kwd-0003">H3K27</kwd>
        <kwd id="humu22946-kwd-0004">Weaver syndrome</kwd>
        <kwd id="humu22946-kwd-0005">childhood cancer</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Canadian Institutes of Health Research (CIHR MOPâ119595)</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <page-count count="7"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>humu22946</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>March 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.6 mode:remove_FC converted:15.04.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <fn-group>
        <fn id="humu22946-note-0002">
          <p>Contract grant sponsors: Canadian Institutes of Health Research (CIHR MOPâ119595).</p>
        </fn>
        <fn id="humu22946-note-0003">
          <p>Communicated by Mark H. Paalman</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <sec id="humu22946-sec-0010">
      <title>Introduction</title>
      <p>The histone methyltransferase EZH2 (<italic>enhancer of zeste homolog 2</italic>) (MIM #601573) is a key epigenetic regulator in mammals. This protein forms the catalytic subunit of the polycombârepressive complex 2 (PRC2) [Kuzmichev etÂ al., <xref rid="humu22946-bib-0018" ref-type="ref">2002</xref>], and is thought to suppress gene transcription epigenetically by adding up to three methyl groups onto lysine residue 27 of histone H3 (H3K27). Epigenetic silencing via EZH2âmediated histone methylation is further supported by the fact that some mutations at the level of H3K27 can inhibit the activity of PRC2 [Lewis etÂ al., <xref rid="humu22946-bib-0020" ref-type="ref">2013</xref>; Pengelly etÂ al., <xref rid="humu22946-bib-0030" ref-type="ref">2013</xref>].</p>
      <p>Somatic mutations of <italic>EZH2</italic> in circulating white blood cells have been shown to be extremely common in hematological malignancies [Lund etÂ al., <xref rid="humu22946-bib-0021" ref-type="ref">2014</xref>]. Sequencing of human diffuse large Bâcell and nonâHodgkin lymphomas revealed recurrent somatic mutations at positions Tyr646, Ala682, and Ala692 (or Tyr641, Ala677, and Ala687 in the shorter EZH2 isoform as referenced in the original publications) [Morin etÂ al., <xref rid="humu22946-bib-0027" ref-type="ref">2010</xref>; Majer etÂ al., <xref rid="humu22946-bib-0022" ref-type="ref">2012</xref>; McCabe etÂ al., <xref rid="humu22946-bib-0024" ref-type="ref">2012a</xref>]. The most frequently mutated residue, tyrosine at position 646, has been reported as mutated to phenylalanine (p.Tyr646Phe), asparagine (p.Tyr646Asn), histidine (p.Tyr646His), and serine (p.Tyr646Ser) [Morin etÂ al., <xref rid="humu22946-bib-0027" ref-type="ref">2010</xref>]. All of these heterozygous single amino acid substitutions have been shown to change the substrate specificity and favor trimethylation of H3K27 (H3K27me2 âH3K27me3) over monomethylation (H3K27me0â H3K27me1) and dimethylation (H3K27me1â H3K27me2). When combined with the activity of the wildâtype (WT) EZH2 copy, which has high affinity for unmethylated H3K27me0 and medium affinity for monomethylated H3K27me1, this results in an overall gainâofâfunction of EZH2 [Sneeringer etÂ al., <xref rid="humu22946-bib-0038" ref-type="ref">2010</xref>; Yap etÂ al., <xref rid="humu22946-bib-0051" ref-type="ref">2011</xref>]. Unlike for Tyr646, mutations at the other two sites have only been reported as specific amino acid substitutions, p.Ala682Gly [McCabe etÂ al., <xref rid="humu22946-bib-0024" ref-type="ref">2012a</xref>] and p.Ala692Val [Majer etÂ al., <xref rid="humu22946-bib-0022" ref-type="ref">2012</xref>].These two alterations also show gainâofâfunction activity but appear to favor different substrates. p.Ala682Gly promotes methyltransferase activity of nearly equal efficiency for all three substrates (H3K27me0/me1/me2), thereby resulting in hypertrimethylation of H3K27 [McCabe etÂ al., <xref rid="humu22946-bib-0024" ref-type="ref">2012a</xref>]. By contrast, p,Ala692Val reduces monomethylation and enhances dimethylation of H3K27 while leaving trimethylation virtually unchanged <italic>in vitro</italic> [Majer etÂ al., <xref rid="humu22946-bib-0022" ref-type="ref">2012</xref>], although global levels of H3K27me3 were found to be increased in a tumorâderived p.Ala692Val mutant cell line, or when this mutant was transiently expressed in a cell line with an EZH2 WT background [Ott etÂ al., <xref rid="humu22946-bib-0029" ref-type="ref">2014</xref>]. Given that additional data support the increased activity of EZH2 in other cancers, possibly independent of its assembly into the PRC2 complex [Xu etÂ al., <xref rid="humu22946-bib-0050" ref-type="ref">2012</xref>], there is intense interest in developing EZH2 inhibitors as potential chemotherapeutic agents [Knutson etÂ al., <xref rid="humu22946-bib-0015" ref-type="ref">2012</xref>; McCabe etÂ al., <xref rid="humu22946-bib-0025" ref-type="ref">2012b</xref>; Qi etÂ al., <xref rid="humu22946-bib-0032" ref-type="ref">2012</xref>; Knutson etÂ al., 2012; Tan etÂ al., <xref rid="humu22946-bib-0040" ref-type="ref">2014</xref>; Van Aller etÂ al., <xref rid="humu22946-bib-0046" ref-type="ref">2014</xref>]. Targeting of other proteins in the complex, such as EED and SUZ12, may also become a useful therapeutic strategy [Tan etÂ al., <xref rid="humu22946-bib-0040" ref-type="ref">2014</xref>], as may disruption of proper PRC2 complex assembly [Kim etÂ al., <xref rid="humu22946-bib-0013" ref-type="ref">2013a</xref>]. Notably, though, inactivating mutations have been found at multiple sites throughout the <italic>EZH2</italic> gene in myeloid disorders and acute lymphoblastic leukemia [Ernst etÂ al., <xref rid="humu22946-bib-0006" ref-type="ref">2010</xref>; Makishima etÂ al., <xref rid="humu22946-bib-0023" ref-type="ref">2010</xref>; Guglielmelli etÂ al., <xref rid="humu22946-bib-0009" ref-type="ref">2011</xref>; Ntziachristos etÂ al., <xref rid="humu22946-bib-0028" ref-type="ref">2012</xref>; Score etÂ al., <xref rid="humu22946-bib-0037" ref-type="ref">2012</xref>; Zhang etÂ al., <xref rid="humu22946-bib-0054" ref-type="ref">2012</xref>; The Cancer Genome Atlas Research Network, <xref rid="humu22946-bib-0044" ref-type="ref">2013</xref>], suggesting that some neoplasms may not respond well to EZH2 inhibition.</p>
      <p>Recently, we and others have shown that <italic>de novo</italic> germline mutations in <italic>EZH2</italic> cause Weaver syndrome (WS; MIM #277590), a rare but wellâdescribed developmental disorder of prenatal onset that features intellectual disability, tall stature, macrocephaly, accelerated bone growth and maturation, and a susceptibility to cancers including hematological malignancies [TattonâBrown etÂ al., <xref rid="humu22946-bib-0041" ref-type="ref">2011</xref>; Gibson etÂ al., <xref rid="humu22946-bib-0008" ref-type="ref">2012</xref>; TattonâBrown etÂ al., 2013; TattonâBrown and Rahman, <xref rid="humu22946-bib-0043" ref-type="ref">2013</xref>]. Aspects of this phenotype can be explained by the role of Ezh2 in craniofacial skeleton formation [Schwarz etÂ al., <xref rid="humu22946-bib-0036" ref-type="ref">2014</xref>]. Though cerebral malformations were not part of the original description of WS [Weaver etÂ al., <xref rid="humu22946-bib-0048" ref-type="ref">1974</xref>], recent clinical reports have documented the presence of neuronal migration disorders in association with physical features of WS [Freeman etÂ al., <xref rid="humu22946-bib-0007" ref-type="ref">1999</xref>; AlâSalem etÂ al., <xref rid="humu22946-bib-0001" ref-type="ref">2013</xref>; TattonâBrown etÂ al., <xref rid="humu22946-bib-0042" ref-type="ref">2013</xref>]. In the case reported by AlâSalem etÂ al. (<xref rid="humu22946-bib-0001" ref-type="ref">2013</xref>), polymicrogyria was proven to be associated with a <italic>de novo</italic> mutation in <italic>EZH2</italic>, confirming the diagnosis of WS in this patient. In the more recent case reported by TattonâBrown etÂ al. (<xref rid="humu22946-bib-0042" ref-type="ref">2013</xref>), pachyâ and polymicrogyria were associated with a truncating variant in <italic>EZH2</italic>, classified as likely pathogenic because parental samples were unavailable.</p>
      <p>Given that both gainâofâfunction and lossâofâfunction mutations in <italic>EZH2</italic> have been associated with human neoplastic disease when acquired during life in somatic cells [Ernst etÂ al., <xref rid="humu22946-bib-0006" ref-type="ref">2010</xref>; Yap etÂ al., <xref rid="humu22946-bib-0051" ref-type="ref">2011</xref>; McCabe etÂ al., <xref rid="humu22946-bib-0024" ref-type="ref">2012a</xref>; Ntziachristos etÂ al., <xref rid="humu22946-bib-0028" ref-type="ref">2012</xref>; Lund etÂ al., <xref rid="humu22946-bib-0021" ref-type="ref">2014</xref>], we hypothesized that germline <italic>de novo</italic> mutations causative of WS would alter EZH2 activity within the PRC2 complex. We further hypothesized that more severe clinical features of WS (such as cerebral migration defects, or the development of leukemia) might be specifically associated with more significant changes in PRC2âmediated methyltransferase activity conferred by individual mutations in <italic>EZH2</italic>.</p>
    </sec>
    <sec id="humu22946-sec-0020">
      <title>Materials and Methods</title>
      <p>To test our hypothesis, we designed recombinant human EZH2 proteins, had them preassembled into PRC2 complexes (BPS Bioscience, San Diego CA), and tested their activity <italic>in vitro</italic> using a wellâaccepted <italic>in vitro</italic> assay [Ernst etÂ al., <xref rid="humu22946-bib-0006" ref-type="ref">2010</xref>; Yap etÂ al., <xref rid="humu22946-bib-0051" ref-type="ref">2011</xref>; Score etÂ al., <xref rid="humu22946-bib-0037" ref-type="ref">2012</xref>]. Mutant EZH2âPRC2 complexes were selected for study based on the rare <italic>de novo</italic> variants observed in our original three patients [Gibson etÂ al., <xref rid="humu22946-bib-0008" ref-type="ref">2012</xref>] and among other patients with WS identified since. Two other variants that had been observed in patients with both WS and neoplastic disease [TattonâBrown etÂ al., <xref rid="humu22946-bib-0041" ref-type="ref">2011</xref>] were also selected.</p>
      <sec id="humu22946-sec-0030">
        <title>Patients</title>
        <p>Clinical data presented here were collected by the physicians who referred the patients to our study. Participating families provided informed consent, and this study was approved by the joint Clinical Research Ethics Board of the University of British Columbia and British Columbia Children's Hospital.</p>
      </sec>
      <sec id="humu22946-sec-0040">
        <title>Sequencing</title>
        <p>Sanger sequencing was performed on PCR products from genomic DNA. PCR primers were used to amplify the 19 coding exons of <italic>EZH2</italic> (exons 2â20; primers available upon request) [Gibson etÂ al., <xref rid="humu22946-bib-0008" ref-type="ref">2012</xref>]. All primer pairs were confirmed to be specific to the <italic>EZH2</italic> gene on chromosome 7 (NC_000007.13: 148504464â148581441) rather than the pseudogene on chromosome 21 (NC_000021.8: 36971977â36972553) using the BLAST function on NCBI at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov//blast/Blast.cgi">http://www.ncbi.nlm.nih.gov//blast/Blast.cgi</ext-link> (GRCh37.p13 assembly). NCBI Reference sequence NM_004456.4 is available from GenBank. This corresponds to the longest isoform of EZH2. All nomenclature of described sequence variants is based on this sequence and follows the guidelines described in <ext-link ext-link-type="uri" xlink:href="http://www.hgvs.org/mutnomen/">http://www.hgvs.org/mutnomen/</ext-link>. Population frequencies for each variant were investigated in the dbSNP database, searchable at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/">http://www.ncbi.nlm.nih.gov/projects/SNP/</ext-link>, and the exome variant server, found at <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>. Functional predictions for previously undescribed variants were done using the PROVEAN and SIFT tools, available at <ext-link ext-link-type="uri" xlink:href="http://provean.jcvi.org/index.php">http://provean.jcvi.org/index.php</ext-link> (PROVEAN v1.1.3). Detailed prediction scores are provided in Supp. Table S1. All described pathogenic variants have been submitted to the LOVD locusâspecific database and can be found at <ext-link ext-link-type="uri" xlink:href="http://www.lovd.nl/EZH2">http://www.lovd.nl/EZH2</ext-link>.</p>
      </sec>
      <sec id="humu22946-sec-0050">
        <title>Histone Methyltransferase Assay</title>
        <p>Core histones were purchased from EMD Millipore (13â107; Billerica MA) and used as methyl acceptors in most of our <italic>in vitro</italic> reactions. This substrate contains a mix of all core histones and H3 peptides at different methylation states, thereby recapitulating the heterogeneity of endogenous nucleosomes. In an alternative assay, biotinylated peptides (mimicking the H3 tail, H3[21â44]) that had been unmethylated (H3K27me0), monomethylated (H3K27me1) or dimethylated (H3K27me2) were used as substrate (Supp. Fig. S1). We purchased PRC2 complexes containing WT EZH2 (51004) or mutant EZH2 from BPS Bioscience [Morin etÂ al., <xref rid="humu22946-bib-0027" ref-type="ref">2010</xref>]. Methyltransferase assays were done using a commonly used kit (17â330; EMD Millipore) [Ernst etÂ al., <xref rid="humu22946-bib-0006" ref-type="ref">2010</xref>; Yap etÂ al., <xref rid="humu22946-bib-0051" ref-type="ref">2011</xref>; Score etÂ al., <xref rid="humu22946-bib-0037" ref-type="ref">2012</xref>] as per manufacturer's instructions. We incubated 250 ng of individual HMTase complexes separately with 0.67 Î¼M <sup>3</sup>HâSâadenosylâmethionine (<sup>3</sup>HâSAM) (Perkin Elmer, Waltham MA) and 2 Î¼g core histones (or 1 Î¼M peptide), in 50 mM TrisâHCl, pH 9.0, and 0.5Â mM DTT for 30 min at 30Â°C in a 10 Î¼l volume. Excess volumes of <sup>3</sup>HâSAM, core histones, and a longer incubation were also tested (Supp. Fig. S2). In all reactions, five or eight microliters were spotted on a P81 square paper (Millipore), washed (three times with 10% tricholoracetic acid and once with 95% ethanol) to remove unincorporated <sup>3</sup>HâMet, airâdried overnight, placed in a glass scintillation vial with 3 ml of scintillation fluid (ScintiSafe Econo1 SX20â5 or Scintisafe 30% SX23â5; Fisher Chemical, Waltham MA), and counted on a 1900TR Liquid Scintillation Analyzer (Perkin Elmer) or LS6500 MultiâPurpose Scintillation Counter (Beckman Coulter, Brea CA). Normalized counts represent the subtraction of background counts (i.e., control tubes with no enzyme added) from total counts.</p>
      </sec>
    </sec>
    <sec id="humu22946-sec-0060">
      <title>Results</title>
      <sec id="humu22946-sec-0070">
        <title>Probands</title>
        <p>Probands 1, 2, and 3 were described previously [Gibson etÂ al., <xref rid="humu22946-bib-0008" ref-type="ref">2012</xref>]. The mutations identified in <italic>EZH2</italic> were c.457_459delTAT (p.Tyr153del), c.2080C&gt;T (p.His694Tyr), and c.394C&gt;T (p.Pro132Ser), respectively.</p>
        <p>Proband 4 was originally published in 2001 [Huffman etÂ al., <xref rid="humu22946-bib-0011" ref-type="ref">2001</xref>]. More detailed clinical features are described in Supp. Table S2. Using Sanger sequencing, we identified a c.394C&gt;T (p.Pro132Ser) mutation in <italic>EZH2</italic>, an alteration previously described in proband 3 from our cohort [Gibson etÂ al., <xref rid="humu22946-bib-0008" ref-type="ref">2012</xref>] and not detected in any of the parents of probands 3 or 4. Proband 4 had a stage 4S neuroblastoma, which subsequently underwent spontaneous resolution, as was commonly observed for this type of tumor [Huffman etÂ al., <xref rid="humu22946-bib-0011" ref-type="ref">2001</xref>]. At this time, a predisposition for neoplasm development in WS and other overgrowth syndromes was already recognized [Huffman etÂ al., <xref rid="humu22946-bib-0011" ref-type="ref">2001</xref>]. This patient also presented with congenital heart defects. Recently, <italic>de novo</italic> mutations in histoneâmodifying genes have been implicated in many cases of congenital heart disease [Zaidi etÂ al., <xref rid="humu22946-bib-0053" ref-type="ref">2013</xref>], further supporting a role for <italic>EZH2</italic> in this individual's phenotype.</p>
        <p>The clinical features of proband 5 are summarized in Supp. Table S2. The most striking and unusual feature is polymicrogyria. Photographs and MRI brain images are presented in Figure <xref rid="humu22946-fig-0001" ref-type="fig">1</xref>. A clinical summary is provided in the Supp. Text along with fetal ultrasound results documenting prenatal onset of excessive growth (Supp. Table S3). We identified a c.2050C&gt;T (p.Arg684Cys) mutation in <italic>EZH2</italic>, confirmed to be <italic>de novo</italic> by trioâbased testing at the BC Children's Hospital Clinical Molecular Genetics Lab. This mutation was previously described in four other WS patients [TattonâBrown etÂ al., <xref rid="humu22946-bib-0041" ref-type="ref">2011</xref>], and thus appears to be a relatively frequent cause of WS.</p>
        <fig fig-type="Figure" xml:lang="en" id="humu22946-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Weaver syndrome proband with polymicrogyria described in this study. <bold>A</bold>: Proband 5 is shown at 2, 4, 6, 8, 12, and 19 months. <bold>B</bold>: Both sides of the hand are shown at 12 months to illustrate the prominent palmar crease. <bold>C</bold>: At 27 months, face with prominent rosy cheeks, profile and ears are shown to confirm the dimple is only present behind the right ear. <bold>D</bold>: At 31 months, mild camptodactyly is seen on the toes and a third nipple is apparent. <bold>E</bold>: Full torso and full body are also shown at 31 months. <bold>F</bold>: Xârays of the hand at 11Â½ months and the knee at 10Â½ months are indicative of advanced bone age. <bold>G</bold>: MRI done at 5 days of age illustrates asymmetric perisylvian polymicrogyria.</p>
          </caption>
          <graphic id="nlm-graphic-3" xlink:href="HUMU-37-301-g001"/>
        </fig>
        <p>The clinical features of probands 6 and 7 are summarized in Supp. Table S2. Further clinical information is provided in the Supp. Text. In both unrelated patients, we identified a c.398A&gt;G (p.Tyr133Cys) <italic>de novo</italic> mutation in <italic>EZH2</italic>. This mutation was predicted damaging by PROVEAN/SIFT (Supp. Table S1).</p>
        <p>We also detected the c.553G&gt;C (p.Asp185His) variant in <italic>EZH2</italic> in individuals referred to our WSâlike cohort. This variant was predicted damaging by SIFT but not by PROVEAN (Supp. Table S1). Clinical features of carriers of this p.(Asp185His) variant (cases 15, 40, 53, 73, and 95) are summarized in Supp. Table S4 and further clinical information is provided in the Supp. Text. Other members of their families were tested at this locus and in all cases the variant was found to be inherited from one of the parents (Supp. Table S4). p.(Asp185His) is reported in dbSNP (rs2302427C&gt;G) with minor allele frequencies of 8% in the 1000 Genomes phase 1 population, 6% in the Exome Variant Server, and 7.7% in a healthy ancestrally diverse cohort screened for common variants in cancerâsusceptibility genes [Bodian etÂ al., <xref rid="humu22946-bib-0002" ref-type="ref">2014</xref>]. Because of its frequency in the general population, the p.(Asp185His) variant cannot in isolation be causative of WS.</p>
      </sec>
      <sec id="humu22946-sec-0080">
        <title>EZH2 Mutations in WS Impair Histone Methyltransferase Activity <italic>In Vitro</italic>
</title>
        <p>In order to determine the functional impact of the <italic>EZH2</italic> mutations observed in WS, EZH2 mutant proteins corresponding to the mutations observed in WS patients were expressed <italic>in vitro</italic> and then assembled together with other artificially expressed members of the PRC2 complex (EED/SUZ12/RbAp48 and AEBP2). Preassembly into the PRC2 complex was necessary because EZH2 requires other members of PRC2 for activity on nucleosomes [Kuzmichev etÂ al., <xref rid="humu22946-bib-0018" ref-type="ref">2002</xref>]. The mutations studied included those identified within our cohort: p.(Tyr153del), p.(His694Tyr), p.(Pro132Ser), p.(Arg684Cys), and p.(Tyr133Cys). The p.(Ala682Thr) and p.(Glu745Lys) mutations were also of interest because of their associations with neuroblastoma, acute lymphoblastic leukemia, and lymphoma in WS patients [TattonâBrown etÂ al., <xref rid="humu22946-bib-0041" ref-type="ref">2011</xref>]. As mentioned above, we also included the common variant p.(Asp185His). WT EZH2 was used as a positive control, and the methyltransferaseâinactive mutant EZH2 p.(Phe672Ile) (equivalent to the inactive fly mutant allele <italic>E</italic>(<italic>z</italic>)<italic><sup>son</sup></italic>
<sup>1</sup> described in Joshi etÂ al. [<xref rid="humu22946-bib-0012" ref-type="ref">2008</xref>]) was used as a negative control. We then measured incorporation of tritiated methyl groups from <sup>3</sup>HâSAM onto mixed core histones in the presence of each EZH2âPRC2 complex (Fig. <xref rid="humu22946-fig-0002" ref-type="fig">2</xref>; Supp. Fig. S3 and Supp. Table S5A). As expected, WT EZH2âPRC2 complex catalyzed the incorporation of <sup>3</sup>H into core histones, consistent with the model whereby it uses <sup>3</sup>HâSAM as the methyl donor and nucleosomes as the recipient substrates for histone methylation [Kuzmichev etÂ al., <xref rid="humu22946-bib-0018" ref-type="ref">2002</xref>]. In contrast, PRC2 complexes containing WSâassociated EZH2 mutants showed reduced histone methyltransferase activity <italic>in vitro</italic> (Fig. <xref rid="humu22946-fig-0002" ref-type="fig">2</xref>; Supp. Fig. S3 and Supp. Table S5A), suggesting that <italic>EZH2</italic> mutations associated with WS are lossâofâfunction (hypomorphic) mutations.</p>
        <fig fig-type="Figure" xml:lang="en" id="humu22946-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Weaver syndrome mutants are impaired in their histone methyltransferase activity <italic>in vitro</italic>. Histone methyltransferase reactions were performed using 2 Î¼g purified core histones and 0.67 Î¼M <sup>3</sup>HâSâadenosylâmethionine (<sup>3</sup>HâSAM). Each reaction was incubated with 250 ng of either wildâtype (WT) or a mutant HMTase complex (or no enzyme controls). Histone methyltransferase activity was measured based on the incorporation of <sup>3</sup>Hâlabeled methyl groups, represented in scintillation counts per minute. Counts were normalized by subtracting background counts (i.e., no enzyme) from the total counts. <bold>A</bold>: Incorporation of tritiated methyl groups from <sup>3</sup>HâSAM onto core histones is shown for each complex: EZH2 WT <bold>â¢</bold>, p.(Phe672Ile) <bold>Ã</bold>, p.(Pro132Ser) <bold>â</bold>, p.(Tyr153del) â³, p.(His694Tyr) â½, p.(Glu745Lys) â´, p.(Ala682Thr) â¾, p.(Arg684Cys) âª, p.(Tyr133Cys) â¡, and p.(Asp185His) â. Error bars represent standard deviation (SD) within the groups âEZH2 WTâ and âEZH2 mutants.â Unpaired tâtest showed statistically significant difference between the two groups (P value &lt; 0.0001). <bold>B</bold>: Incorporation of tritiated methyl groups from <sup>3</sup>HâSAM onto core histones is shown for the positive control EZH2 WT, the negative control EZH2 (p.Phe672Ile), and the mutant complex with activity closest to WT, namely, EZH2 (p.Pro132Ser). Error bars represent SD of four independent replicates for the controls, and three independent replicates for the mutant EZH2 (p.Pro132Ser). Oneâway ANOVA showed statistically significant difference between all groups (overall P value &lt; 0.0001; P values between WT and p.(Phe672Ile), between p.(Phe672Ile) and p.(Pro132Ser), and between WT and p.(Pro132Ser) were all &lt;0.05).</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="HUMU-37-301-g002"/>
        </fig>
      </sec>
      <sec id="humu22946-sec-0090">
        <title>The Common p.(Asp185His) Variant Also Appears to Impair Histone Methyltransferase Activity <italic>In Vitro</italic>
</title>
        <p>Surprisingly, EZH2 p.(Asp185His) also showed impaired histone methyltransferase activity in this <italic>in vitro</italic> assay (Fig. <xref rid="humu22946-fig-0002" ref-type="fig">2</xref>A; Supp. Fig. S3). Based on the frequency of this variant and the rarity of WS, p.(Asp185His) cannot by itself be causative of WS. However, based on the number of replicates we performed under varied conditions (Supp. Fig. S2 and Supp. Tables S5B and C), we believe this result to be reproducible and to reflect accurately the activity of this enzyme variant under these artificial conditions.</p>
      </sec>
    </sec>
    <sec id="humu22946-sec-0100">
      <title>Discussion</title>
      <sec id="humu22946-sec-0110">
        <title>Expanding the Phenotype of WS to Include Neuronal Migration Disorders</title>
        <p>Brain imaging in proband 5 (Fig. <xref rid="humu22946-fig-0001" ref-type="fig">1</xref>G) was consistent with that reported on two prior occasions in different children with WS [Freeman etÂ al., <xref rid="humu22946-bib-0007" ref-type="ref">1999</xref>; AlâSalem etÂ al., <xref rid="humu22946-bib-0001" ref-type="ref">2013</xref>]. In each previous case, and in our case, there was asymmetric perisylvian polymicrogyria that appeared more severe on the right side, as well as mildly enlarged lateral ventricles. The report by Freeman etÂ al. (<xref rid="humu22946-bib-0007" ref-type="ref">1999</xref>) described pachygyria, but based on review of the published images (W. Dobyns), we believe the findings are more consistent with perisylvian polymicrogyria. The image shown in the report by AlâSalem etÂ al. (<xref rid="humu22946-bib-0001" ref-type="ref">2013</xref>) demonstrates enlarged extraâaxial fluid spaces over the brain, similar in appearance to the polymicrogyria observed among megalencephaly syndromes associated with PI3KâAKT pathway mutations [Mirzaa etÂ al., <xref rid="humu22946-bib-0026" ref-type="ref">2012</xref>]. However, neither hydrocephalus nor Chiari malformations were seen in these WS patients. TattonâBrown etÂ al. (<xref rid="humu22946-bib-0042" ref-type="ref">2013</xref>) also reported a case with pachyâ and polymicrogyria, but no images were published.</p>
        <p>Our proband 5 has the recurrent p.(Arg684Cys) <italic>de novo</italic> mutation, the patient with polymicrogyria and WS described by AlâSalem etÂ al. (<xref rid="humu22946-bib-0001" ref-type="ref">2013</xref>) was shown to have a <italic>de novo</italic> p.(Glu745Lys) mutation, and the patient from TattonâBrown etÂ al. (<xref rid="humu22946-bib-0042" ref-type="ref">2013</xref>) had an <italic>EZH2</italic> variant predicted to truncate the protein at position 732. The association of polymicrogyria with WS in four independent cases, two of which have molecular confirmation of <italic>de novo</italic> mutations in different exons of <italic>EZH2</italic> and another of which has a truncating variant in the last exon, strongly supports a causal association between <italic>EZH2</italic> mutations and neuronal migration defects in some patients with WS. EZH2 has been shown to control the decision between selfârenewal and differentiation in the cerebral cortex, and inhibition of PRC2 complex activity had been shown to shift the balance toward differentiation [Pereira etÂ al., <xref rid="humu22946-bib-0031" ref-type="ref">2010</xref>]. Furthermore, EZH2 has also been shown to orchestrate neuronal migration in the corticoâpontoâcerebellar pathway in mice [Di Meglio etÂ al., <xref rid="humu22946-bib-0005" ref-type="ref">2013</xref>]. The possibility that diminished PRC2 complex activity could lead to premature neuronal differentiation, possibly at ectopic sites along the normal migration pathway, offers a plausible explanation for the cortical patterning defects seen in patients with WS and pachyâ or polymicrogyria.</p>
        <p>Thus, in addition to their known risk for neoplastic disease, patients with WS should be considered to be at risk for neuronal migration disorders, and physicians should have a low threshold for ordering cranial imaging studies. Similarly, children with overgrowth and cerebral migration disorders could be tested for rare variants in <italic>EZH2</italic>, and physicians performing prenatal diagnosis in the context of a fetus with polymicrogyria should consider the possibility of WS.</p>
        <p>Given the large number of individuals now being studied with highâthroughput nextâgeneration sequencing, rare variants in <italic>EZH2</italic> that are discovered through targeted sequencing panels, exome sequencing, or wholeâgenome sequencing should be considered carefully in the context of clinical findings such as overgrowth phenotypes, cerebral malformations, and neoplastic disease. For highly heterogeneous disorders such as overgrowth syndromes, techniques such as exome sequencing are becoming costâeffective for diagnosis at an early stage of the workup. An estimate of diagnostic costs incurred during the workup of proband 5 is presented in Supp. Table S6, for theoretical comparison to early exome sequencing (though in his particular case, <italic>EZH2</italic> was selected on a candidate gene basis).</p>
      </sec>
      <sec id="humu22946-sec-0120">
        <title>WS Mutations and Neoplastic Disease</title>
        <p>With somatic mutations in <italic>EZH2</italic> having been associated to both gain and loss of histone methyltransferase function, it was important to investigate mutations found in WS patients who had also developed malignancies. To date, none of the three cases from our original report have been diagnosed with neoplastic disease. However, proband 4 had a nonmetastatic stage 4S neuroblastoma in his left adrenal gland. Our functional analysis of the EZH2 p.(Pro132Ser) mutant complex suggested a lossâofâfunction effect, consistent with a previous report of this variant in the context of myeloid disorders [Guglielmelli etÂ al., <xref rid="humu22946-bib-0009" ref-type="ref">2011</xref>]. Proband 6 had a prenatal neuroblastoma in the right adrenal gland that was successfully removed surgically shortly after birth, and the EZH2 p.(Tyr133Cys) mutant complex also appeared to be lossâofâfunction in our assay. The other two mutant complexes containing mutations found in patients with malignancies, EZH2 p.(Arg682Thr), and p.(Glu745Lys) [TattonâBrown etÂ al., <xref rid="humu22946-bib-0041" ref-type="ref">2011</xref>], also showed lossâofâfunction <italic>in vitro</italic>, suggesting that the mechanism driving cancer in WS patients resembles that of myeloid disorders and acute lymphoblastic leukemia rather than that of diffuse large Bâcell and nonâHodgkin lymphomas. Furthermore, the p.(Arg684Cys) mutation reported in several independent cases [TattonâBrown etÂ al., <xref rid="humu22946-bib-0041" ref-type="ref">2011</xref>] and identified in proband 5, which has not yet been associated with malignancy development in WS but appears to be a true recurrent mutation, had already been described as likely inactivating in myeloid disorders [Ernst etÂ al., <xref rid="humu22946-bib-0006" ref-type="ref">2010</xref>]. Overall, all <italic>de novo</italic> WSâassociated <italic>EZH2</italic> mutations showed impaired histone methyltransferase activity <italic>in vitro</italic>, particularly with reduced ability to monomethylate H3K27 (Supp. Fig. S1 and Supp. Table S5D). Impaired histone methyltransferase activity had previously been observed among <italic>NSD1</italic> mutations causing Sotos syndrome (MIM #117550) [Qiao etÂ al., <xref rid="humu22946-bib-0033" ref-type="ref">2011</xref>; Kudithipudi etÂ al., <xref rid="humu22946-bib-0017" ref-type="ref">2014</xref>], which is another overgrowth syndrome that shares significant phenotypic overlap with WS [TattonâBrown and Rahman, <xref rid="humu22946-bib-0043" ref-type="ref">2013</xref>]. Based on these results, we suggest that EZH2 inhibitors currently being developed against various cancers [Knutson etÂ al., <xref rid="humu22946-bib-0015" ref-type="ref">2012</xref>; McCabe etÂ al., <xref rid="humu22946-bib-0025" ref-type="ref">2012b</xref>; Qi etÂ al., <xref rid="humu22946-bib-0032" ref-type="ref">2012</xref>; Knutson etÂ al., 2013] may not be of specific benefit in WS. Importantly, we did not assay PRC2âindependent functions of EZH2, so additional complexity in the functional effects of diseaseâassociated EZH2 mutations remains to be unraveled.</p>
      </sec>
      <sec id="humu22946-sec-0130">
        <title>Methyltransferase Activity of p.(Asp185His)</title>
        <p>We identified the p.(Asp185His) variant in five individuals who were referred for WSâlike features, including macrocephaly. This variant has been found in multiple healthy controls, as well as among individuals affected with generalized overgrowth or acute leukemia [TattonâBrown etÂ al., <xref rid="humu22946-bib-0041" ref-type="ref">2011</xref>; Grossmann etÂ al., <xref rid="humu22946-bib-0010" ref-type="ref">2012</xref>]. Importantly, recent genomeâwide association studies for human height and for infant head circumference have not identified this variant as a risk factor for either of these quantitative traits [Taal etÂ al., <xref rid="humu22946-bib-0039" ref-type="ref">2012</xref>; Wood etÂ al., <xref rid="humu22946-bib-0049" ref-type="ref">2014</xref>]. Thus, population genetic evidence supports the classification of the p.(Asp185His) variant as a common, benign SNP (singleânucleotide polymorphism). In this context, the fact that our functional work suggests impaired histone methyltransferase activity for this mutant is notable. Based on careful repetition of our assays with different lot numbers of the WT protein and under varied conditions (Fig. <xref rid="humu22946-fig-0002" ref-type="fig">2</xref>; Supp. Figs. S2 and S3), we do believe our <italic>in vitro</italic> results to be reproducible. Given the reproducibility of our assay in our hands and the use of a similar assay by multiple other groups, we do not believe the low methyltransferase activity exhibited by the p.(Asp185His) protein variant in this assay is indicative of experimental error. Rather, we believe that our results reflect the true activity of this variant under this select set of experimental conditions. Nevertheless, given the lack of a specific phenotype for p.(Asp185His) carriers, these <italic>in vitro</italic> results may not reflect its true activity <italic>in vivo</italic>. On this basis, we must conclude that this particular <italic>in vitro</italic> assay cannot be used in isolation to assess the potential pathogenicity of novel <italic>EZH2</italic> variants. Instead, pathogenicity should be assessed based on the sum total of available evidence from familyâspecific cosegregation with disease phenotypes, population genetics, and, where available, other orthogonal lines of functional evidence. The possibility of âpseudodeficiency allelesâ is an uncommon but known phenomenon whereby some protein variants manifest impaired activity by <italic>in vitro</italic> assays but have no demonstrable phenotypic effects <italic>in vivo</italic> [CoulterâMackie and Gagnier, <xref rid="humu22946-bib-0004" ref-type="ref">2003</xref>; Yasuda etÂ al., <xref rid="humu22946-bib-0052" ref-type="ref">2003</xref>; Tomatsu etÂ al., <xref rid="humu22946-bib-0045" ref-type="ref">2009</xref>]. To understand the discrepancy between the predicted (normal) activity of a common protein variant and its observed (deficient) activity more fully would require more definitive studies such as determination of the binding constant (<italic>K</italic>
<sub>m</sub>) for substrates, assays over the linear portion of the product versus time curve, and careful substudies of the different enzymatic steps for a variety of different rare and common protein variants.</p>
      </sec>
      <sec id="humu22946-sec-0140">
        <title>Histone Methyltransferase Activity Does Not Correlate with Phenotypic Severity</title>
        <p>We chose to assay EZH2 protein variants that represented a wide variety of WS phenotypes. We had hypothesized that more severe clinical features of WS (such as cerebral migration defects, or the development of malignancy) might be associated with mutations in specific protein domains that were in turn associated with more striking alterations of histone methyltransferase activity. However, we observed no clear correlation between these parameters. We also observed no correlation between clinical severity and profiles of substrate specificity (Supp. Fig. S1). Our results are consistent with Guglielmelli etÂ al. (<xref rid="humu22946-bib-0009" ref-type="ref">2011</xref>) who observed no correlation between <italic>EZH2</italic> mutational status and hematologic or clinical parameters in patients with myelofibrosis. This lack of phenotype/genotype correlation suggests that factors apart from histone methyltransferase function (such as the presence of modifier genes, other epigenetic modifications such as H3K4 methylation, or stochastic modifiers) might explain the phenotypic differences observed in WS patients. Activity of accessory proteins that are absent from our <italic>in vitro</italic> assay might also change the conformation of the PRC2 complex and influence the resulting phenotype. Such factors include the presence of PHF1 [Sarma etÂ al., <xref rid="humu22946-bib-0035" ref-type="ref">2008</xref>], the activity of NFâkB [Lee etÂ al., <xref rid="humu22946-bib-0019" ref-type="ref">2011</xref>], WNT [Wang etÂ al., <xref rid="humu22946-bib-0047" ref-type="ref">2010</xref>], or Akt, that modifies EZH2 postâtranslationally [Cha etÂ al., <xref rid="humu22946-bib-0003" ref-type="ref">2005</xref>]. Alternatively, the activity of WS mutants on nonhistone substrates, such as STAT3 [Kim etÂ al., <xref rid="humu22946-bib-0014" ref-type="ref">2013b</xref>] or JARID2 [Sanulli etÂ al., <xref rid="humu22946-bib-0034" ref-type="ref">2015</xref>], may be a more important determinant of the ultimate phenotype of WS patients.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data">
        <p>Disclaimer: Supplementary materials have been peerâreviewed but not copyedited.</p>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>Supporting Information</p>
        </caption>
        <media xlink:href="HUMU-37-301-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="humu22946-sec-0150">
      <title>Acknowledgments</title>
      <p>We would like to thank the families for agreeing to participate in our study. We are also extremely grateful for the expert comments from Dr. Gregg Morin regarding our enzymatic assay. Further, we gratefully acknowledge the assistance of Drs. Brett Casey and Tanya Nelson in the clinical testing of <italic>EZH2</italic> mutations among proband 5 and his family members, as well as Dr. Kym M. Boycott and Rebecca L. Hood for testing of <italic>EZH2</italic> in proband 6. This work was funded by the Government of Canada through the Canadian Institutes of Health Research (CIHR MOPâ119595). WTG received salary support via Clinician Scientist Awards from the CIHR and from the Child and Family Research Institute. ASAC is supported by a Doctoral Grant from the FundaÃ§Ã£o para a CiÃªncia e a Tecnologia (Government of Portugal and European Union joint grant).</p>
    </ack>
    <ref-list id="humu22946-bibl-0001">
      <title>References</title>
      <ref id="humu22946-bib-0001">
        <mixed-citation publication-type="journal" id="humu22946-cit-0001">
<string-name>
<surname>AlâSalem</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Alshammari</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Hassan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Alazami</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Alkuraya</surname>
<given-names>FS</given-names>
</string-name>. <year>2013</year>
<article-title>Weaver syndrome and defective cortical development: a rare association</article-title>. <source>Am J Med Genet A</source>
<volume>161A</volume>:<fpage>225</fpage>â<lpage>227</lpage>.<pub-id pub-id-type="pmid">23239504</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0002">
        <mixed-citation publication-type="journal" id="humu22946-cit-0002">
<string-name>
<surname>Bodian</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>McCutcheon</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Kothiyal</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Huddleston</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Iyer</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Vockley</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Niederhuber</surname>
<given-names>JE</given-names>
</string-name>. <year>2014</year>
<article-title>Germline variation in cancerâsusceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing</article-title>. <source>PLoS One</source>
<volume>9</volume>:<fpage>e94554</fpage>.<pub-id pub-id-type="pmid">24728327</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0003">
        <mixed-citation publication-type="journal" id="humu22946-cit-0003">
<string-name>
<surname>Cha</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Ping</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Otte</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Hung</surname>
<given-names>MC</given-names>
</string-name>. <year>2005</year>
<article-title>Aktâmediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3</article-title>. <source>Science</source>
<volume>310</volume>:<fpage>306</fpage>â<lpage>310</lpage>.<pub-id pub-id-type="pmid">16224021</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0004">
        <mixed-citation publication-type="journal" id="humu22946-cit-0004">
<string-name>
<surname>CoulterâMackie</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Gagnier</surname>
<given-names>L</given-names>
</string-name>. <year>2003</year>
<article-title>Spectrum of mutations in the arylsulfatase A gene in a Canadian DNA collection including two novel frameshift mutations, a new missense mutation (C488R) and an MLD mutation (R84Q) in cis with a pseudodeficiency allele</article-title>. <source>Mol Genet Metab</source>
<volume>79</volume>:<fpage>91</fpage>â<lpage>98</lpage>.<pub-id pub-id-type="pmid">12809638</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0005">
        <mixed-citation publication-type="journal" id="humu22946-cit-0005">
<string-name>
<surname>Di Meglio</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kratochwil</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Vilain</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Loche</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vitobello</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yonehara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hrycaj</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Roska</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>AHFM</given-names>
</string-name>, <string-name>
<surname>Eichmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wellik</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ducret</surname>
<given-names>S</given-names>
</string-name>, etÂ al. <year>2013</year>
<article-title>Ezh2 orchestrates topographic migration and connectivity of mouse precerebellar neurons</article-title>. <source>Science</source>
<volume>339</volume>:<fpage>204</fpage>â<lpage>207</lpage>.<pub-id pub-id-type="pmid">23307742</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0006">
        <mixed-citation publication-type="journal" id="humu22946-cit-0006">
<string-name>
<surname>Ernst</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chase</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Score</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>HidalgoâCurtis</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Bryant</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Waghorn</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zoi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Reiter</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hochhaus</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Drexler</surname>
<given-names>HG</given-names>
</string-name>, etÂ al. <year>2010</year>
<article-title>Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders</article-title>. <source>Nat Genet</source>
<volume>42</volume>:<fpage>722</fpage>â<lpage>726</lpage>.<pub-id pub-id-type="pmid">20601953</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0007">
        <mixed-citation publication-type="journal" id="humu22946-cit-0007">
<string-name>
<surname>Freeman</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Hoon</surname>
<given-names>AH</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Breiter</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Hamosh</surname>
<given-names>A.</given-names>
</string-name>
<year>1999</year>
<article-title>Pachygyria in Weaver syndrome</article-title>. <source>Am J Med Genet</source>
<volume>86</volume>:<fpage>395</fpage>â<lpage>397</lpage>.<pub-id pub-id-type="pmid">10494098</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0008">
        <mixed-citation publication-type="journal" id="humu22946-cit-0008">
<string-name>
<surname>Gibson</surname>
<given-names>WT</given-names>
</string-name>, <string-name>
<surname>Hood</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Zhan</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Bulman</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Fejes</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mungall</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Eydoux</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>BabulâHirji</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>An</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Marra</surname>
<given-names>MA</given-names>
</string-name>, <collab collab-type="authors">FORGE Canada Consortium</collab>
, etÂ al. <year>2012</year>
<article-title>Mutations in EZH2 cause Weaver syndrome</article-title>. <source>Am J Hum Genet</source>
<volume>90</volume>:<fpage>110</fpage>â<lpage>118</lpage>.<pub-id pub-id-type="pmid">22177091</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0009">
        <mixed-citation publication-type="journal" id="humu22946-cit-0009">
<string-name>
<surname>Guglielmelli</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Biamonte</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Score</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>HidalgoâCurtis</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cervantes</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Maffioli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fanelli</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ernst</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Winkelman</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Zoi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Reiter</surname>
<given-names>A</given-names>
</string-name>, etÂ al. <year>2011</year>
<article-title>EZH2 mutational status predicts poor survival in myelofibrosis</article-title>. <source>Blood</source>
<volume>118</volume>:<fpage>5227</fpage>â<lpage>5234</lpage>.<pub-id pub-id-type="pmid">21921040</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0010">
        <mixed-citation publication-type="journal" id="humu22946-cit-0010">
<string-name>
<surname>Grossmann</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Bacher</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kohlmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Artusi</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>HU</given-names>
</string-name>, <string-name>
<surname>Dugas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schnittger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Alpermann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kern</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Haferlach</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Haferlach</surname>
<given-names>C</given-names>
</string-name>. <year>2012</year>
<article-title>EZH2 mutations and their association with PICALMâMLLT10 positive acute leukaemia</article-title>. <source>Br J Haematol</source>
<volume>157</volume>:<fpage>387</fpage>â<lpage>390</lpage>.<pub-id pub-id-type="pmid">22235851</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0011">
        <mixed-citation publication-type="journal" id="humu22946-cit-0011">
<string-name>
<surname>Huffman</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>McCandless</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jasty</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Matloub</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>HB</given-names>
</string-name>, <string-name>
<surname>Weaver</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>MM</given-names>
<suffix>Jr</suffix>
</string-name>. <year>2001</year>
<article-title>Weaver syndrome with neuroblastoma and cardiovascular anomalies</article-title>. <source>Am J Med Genet</source>
<volume>99</volume>:<fpage>252</fpage>â<lpage>255</lpage>.<pub-id pub-id-type="pmid">11241499</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0012">
        <mixed-citation publication-type="journal" id="humu22946-cit-0012">
<string-name>
<surname>Joshi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Carrington</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ketel</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>JA</given-names>
</string-name>. <year>2008</year>
<article-title>Dominant alleles identify SET domain residues required for histone methyltransferase of polycomb repressive complex 2</article-title>. <source>J Biol Chem</source>
<volume>283</volume>:<fpage>27757</fpage>â<lpage>27766</lpage>.<pub-id pub-id-type="pmid">18693240</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0013">
        <mixed-citation publication-type="journal" id="humu22946-cit-0013">
<string-name>
<surname>Kim</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Bird</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Neff</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kerenyi</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Walensky</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Orkin</surname>
<given-names>SH</given-names>
</string-name>. <year>2013a</year>
<article-title>Targeted disruption of the EZH2âEED complex inhibits EZH2âdependent cancer</article-title>. <source>Nat Chem Biol</source>
<volume>9</volume>:<fpage>643</fpage>â<lpage>650</lpage>.<pub-id pub-id-type="pmid">23974116</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0014">
        <mixed-citation publication-type="journal" id="humu22946-cit-0014">
<string-name>
<surname>Kim</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>YT</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rheey</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nakano</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Joo</surname>
<given-names>KM</given-names>
</string-name>, etÂ al. <year>2013b</year>
<article-title>Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stemâlike Cells</article-title>. <source>Cancer Cell</source>
<volume>23</volume>:<fpage>839</fpage>â<lpage>852</lpage>.<pub-id pub-id-type="pmid">23684459</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0015">
        <mixed-citation publication-type="journal" id="humu22946-cit-0015">
<string-name>
<surname>Knutson</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Wigle</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Warholic</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Sneeringer</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Allain</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Klaus</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Sacks</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Raimondi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Majer</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Porter Scott</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>L</given-names>
</string-name>, etÂ al. <year>2012</year>
<article-title>A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells</article-title>. <source>Nat Chem Biol</source>
<volume>8</volume>:<fpage>890</fpage>â<lpage>896</lpage>.<pub-id pub-id-type="pmid">23023262</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0016">
        <mixed-citation publication-type="journal" id="humu22946-cit-0016">
<string-name>
<surname>Knutson</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Warholic</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Wigle</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Klaus</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Allain</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Raimondi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Porter Scott</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chesworth</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moyer</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Copeland</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Richon</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Pollock</surname>
<given-names>RM</given-names>
</string-name>, etÂ al. <year>2013</year>
<article-title>Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>110</volume>:<fpage>7922</fpage>â<lpage>7927</lpage>.<pub-id pub-id-type="pmid">23620515</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0017">
        <mixed-citation publication-type="journal" id="humu22946-cit-0017">
<string-name>
<surname>Kudithipudi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lungu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rathert</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Happel</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Jeltsch</surname>
<given-names>A</given-names>
</string-name>. <year>2014</year>
<article-title>Substrate specificity analysis and novel substrates of the protein lysine methyltransferase NSD1</article-title>. <source>Chem Biol</source>
<volume>21</volume>:<fpage>226</fpage>â<lpage>237</lpage>.<pub-id pub-id-type="pmid">24412544</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0018">
        <mixed-citation publication-type="journal" id="humu22946-cit-0018">
<string-name>
<surname>Kuzmichev</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nishioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>ErdjumentâBromage</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tempst</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Reinberg</surname>
<given-names>D</given-names>
</string-name>. <year>2002</year>
<article-title>Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of Zeste protein</article-title>. <source>Genes Dev</source>
<volume>16</volume>:<fpage>2893</fpage>â<lpage>2905</lpage>.<pub-id pub-id-type="pmid">12435631</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0019">
        <mixed-citation publication-type="journal" id="humu22946-cit-0019">
<string-name>
<surname>Lee</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Aau</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Guan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Karuturi</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Liou</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>Q</given-names>
</string-name>. <year>2011</year>
<article-title>Contextâspecific regulation of NFâkappaB target gene expression by EZH2 in breast cancers</article-title>. <source>Mol Cell</source>
<volume>43</volume>:<fpage>798</fpage>â<lpage>810</lpage>.<pub-id pub-id-type="pmid">21884980</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0020">
        <mixed-citation publication-type="journal" id="humu22946-cit-0020">
<string-name>
<surname>Lewis</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Koletsky</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Cordero</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Banaszynski</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Muir</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Becher</surname>
<given-names>OJ</given-names>
</string-name>, <string-name>
<surname>Allis</surname>
<given-names>CD</given-names>
</string-name>. <year>2013</year>
<article-title>Inhibition of PRC2 activity by a gainâofâfunction H3 mutation found in pediatric glioblastoma</article-title>. <source>Science</source>
<volume>340</volume>:<fpage>857</fpage>â<lpage>861</lpage>.<pub-id pub-id-type="pmid">23539183</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0021">
        <mixed-citation publication-type="journal" id="humu22946-cit-0021">
<string-name>
<surname>Lund</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Copland</surname>
<given-names>M</given-names>
</string-name>. <year>2014</year>
<article-title>EZH2 in normal and malignant hematopoiesis</article-title>. <source>Leukemia</source>
<volume>28</volume>:<fpage>44</fpage>â<lpage>49</lpage>.<pub-id pub-id-type="pmid">24097338</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0022">
        <mixed-citation publication-type="journal" id="humu22946-cit-0022">
<string-name>
<surname>Majer</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Knutson</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Kuntz</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Keilhack</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Moyer</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Richon</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Copeland</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Wigle</surname>
<given-names>TJ</given-names>
</string-name>. <year>2012</year>
<article-title>A687V EZH2 is a gainâofâfunction mutation found in lymphoma patients</article-title>. <source>FEBS Lett</source>
<volume>586</volume>:<fpage>3448</fpage>â<lpage>3451</lpage>.<pub-id pub-id-type="pmid">22850114</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0023">
        <mixed-citation publication-type="journal" id="humu22946-cit-0023">
<string-name>
<surname>Makishima</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Jankowska</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Tiu</surname>
<given-names>RV</given-names>
</string-name>, <string-name>
<surname>Szpurka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sugimoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Saunthararajah</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Guinta</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Keddache</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Putnam</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sekeres</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>AR</given-names>
</string-name>, etÂ al. <year>2010</year>
<article-title>Novel homoâ and hemizygous mutations in EZH2 in myeloid malignancies</article-title>. <source>Leukemia</source>
<volume>24</volume>:<fpage>1799</fpage>â<lpage>1804</lpage>.<pub-id pub-id-type="pmid">20724984</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0024">
        <mixed-citation publication-type="journal" id="humu22946-cit-0024">
<string-name>
<surname>McCabe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Graves</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Ganji</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Diaz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Halsey</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Smitheman</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Ott</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Pappalardi</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Della Pietra</surname>
<given-names>A</given-names>
<suffix>3rd</suffix>
</string-name>, etÂ al. <year>2012a</year>
<article-title>Mutation of A677 in histone methyltransferase EZH2 in human Bâcell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>109</volume>:<fpage>2989</fpage>â<lpage>2994</lpage>.<pub-id pub-id-type="pmid">22323599</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0025">
        <mixed-citation publication-type="journal" id="humu22946-cit-0025">
<string-name>
<surname>McCabe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Ott</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Ganji</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Korenchuk</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Van Aller</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Graves</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Della Pietra</surname>
<given-names>A</given-names>
<suffix>3rd</suffix>
</string-name>, <string-name>
<surname>Diaz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>LaFrance</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Mellinger</surname>
<given-names>M</given-names>
</string-name>, etÂ al. <year>2012b</year>
<article-title>EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2âactivating mutations</article-title>. <source>Nature</source>
<volume>492</volume>:<fpage>108</fpage>â<lpage>112</lpage>.<pub-id pub-id-type="pmid">23051747</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0026">
        <mixed-citation publication-type="journal" id="humu22946-cit-0026">
<string-name>
<surname>Mirzaa</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Conway</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>LermanâSagie</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Siegel</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>deVries</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Lev</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hopkins</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>JM</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Dobyns</surname>
<given-names>WB</given-names>
</string-name>. <year>2012</year>
<article-title>Megalencephalyâcapillary malformation (MCAP) and megalencephalyâpolydactylyâpolymicrogyriaâhydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis</article-title>. <source>Am J Med Genet A</source>
<volume>158A</volume>:<fpage>269</fpage>â<lpage>291</lpage>.<pub-id pub-id-type="pmid">22228622</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0027">
        <mixed-citation publication-type="journal" id="humu22946-cit-0027">
<string-name>
<surname>Morin</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Severson</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Mungall</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>An</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Goya</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Woolcock</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Kuchenbauer</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yap</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Humphries</surname>
<given-names>RK</given-names>
</string-name>, etÂ al. <year>2010</year>
<article-title>Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large Bâcell lymphomas of germinalâcenter origin</article-title>. <source>Nat Genet</source>
<volume>42</volume>:<fpage>181</fpage>â<lpage>185</lpage>.<pub-id pub-id-type="pmid">20081860</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0028">
        <mixed-citation publication-type="journal" id="humu22946-cit-0028">
<string-name>
<surname>Ntziachristos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tsirigos</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Van Vlierberghe</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Nedjic</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Trimarchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Flaherty</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>FerresâMarco</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>da Ros</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Siegle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Asp</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hadler</surname>
<given-names>M</given-names>
</string-name>, etÂ al. <year>2012</year>
<article-title>Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia</article-title>. <source>Nat Med</source>
<volume>18</volume>:<fpage>298</fpage>â<lpage>301</lpage>.<pub-id pub-id-type="pmid">22237151</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0029">
        <mixed-citation publication-type="journal" id="humu22946-cit-0029">
<string-name>
<surname>Ott</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Graves</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Pappalardi</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Huddleston</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Halsey</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Groy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dul</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Bai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Annan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Verma</surname>
<given-names>SK</given-names>
</string-name>, etÂ al. <year>2014</year>
<article-title>A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation</article-title>. <source>Mol Cancer Ther</source>
<volume>13</volume>:<fpage>3062</fpage>â<lpage>3073</lpage>.<pub-id pub-id-type="pmid">25253781</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0030">
        <mixed-citation publication-type="journal" id="humu22946-cit-0030">
<string-name>
<surname>Pengelly</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Copur</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Jackle</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Herzig</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>J</given-names>
</string-name>. <year>2013</year>
<article-title>A histone mutant reproduces the phenotype caused by loss of histoneâmodifying factor Polycomb</article-title>. <source>Science</source>
<volume>339</volume>:<fpage>698</fpage>â<lpage>699</lpage>.<pub-id pub-id-type="pmid">23393264</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0031">
        <mixed-citation publication-type="journal" id="humu22946-cit-0031">
<string-name>
<surname>Pereira</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Sansom</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dobenecker</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Tarakhovsky</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Livesey</surname>
<given-names>FJ</given-names>
</string-name>. <year>2010</year>
<article-title>Ezh2, the histone methyltransferase of PRC2, regulates the balance between selfârenewal and differentiation in the cerebral cortex</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>107</volume>:<fpage>15957</fpage>â<lpage>15962</lpage>.<pub-id pub-id-type="pmid">20798045</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0032">
        <mixed-citation publication-type="journal" id="humu22946-cit-0032">
<string-name>
<surname>Qi</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chuai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ardayfio</surname>
<given-names>O</given-names>
</string-name>, etÂ al. <year>2012</year>
<article-title>Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>109</volume>:<fpage>21360</fpage>â<lpage>21365</lpage>.<pub-id pub-id-type="pmid">23236167</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0033">
        <mixed-citation publication-type="journal" id="humu22946-cit-0033">
<string-name>
<surname>Qiao</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Reinberg</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>RM</given-names>
</string-name>. <year>2011</year>
<article-title>The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation</article-title>. <source>J Biol Chem</source>
<volume>286</volume>:<fpage>8361</fpage>â<lpage>8368</lpage>.<pub-id pub-id-type="pmid">21196496</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0034">
        <mixed-citation publication-type="journal" id="humu22946-cit-0034">
<string-name>
<surname>Sanulli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Justin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Teissandier</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ancelin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Portoso</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Caron</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Michaud</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lombard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>da Rocha</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Offer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Loew</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Servant</surname>
<given-names>N</given-names>
</string-name>, etÂ al. <year>2015</year>
<article-title>Jarid2 methylation via the PRC2 complex regulates H3K27me3 deposition during cell differentiation</article-title>. <source>Mol Cell</source>
<volume>57</volume>:<fpage>769</fpage>â<lpage>783</lpage>.<pub-id pub-id-type="pmid">25620564</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0035">
        <mixed-citation publication-type="journal" id="humu22946-cit-0035">
<string-name>
<surname>Sarma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Margueron</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ivanov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pirrotta</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Reinberg</surname>
<given-names>D</given-names>
</string-name>. <year>2008</year>
<article-title>Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo</article-title>. <source>Mol Cell Biol</source>
<volume>28</volume>:<fpage>2718</fpage>â<lpage>2731</lpage>.<pub-id pub-id-type="pmid">18285464</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0036">
        <mixed-citation publication-type="journal" id="humu22946-cit-0036">
<string-name>
<surname>Schwarz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Varum</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zemke</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>SchÃ¶ler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baggiolini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Draganova</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Koseki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>SchÃ¼beler</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sommer</surname>
<given-names>L</given-names>
</string-name>. <year>2014</year>
<article-title>Ezh2 is required for neural crestâderived cartilage and bone formation</article-title>. <source>Development</source>
<volume>141</volume>:<fpage>867</fpage>â<lpage>877</lpage>.<pub-id pub-id-type="pmid">24496623</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0037">
        <mixed-citation publication-type="journal" id="humu22946-cit-0037">
<string-name>
<surname>Score</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>HidalgoâCurtis</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Winkelmann</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Skinner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ward</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zoi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ernst</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Stegelmann</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>DÃ¶hner</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Chase</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cross</surname>
<given-names>NC</given-names>
</string-name>. <year>2012</year>
<article-title>Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms</article-title>. <source>Blood</source>
<volume>119</volume>:<fpage>1208</fpage>â<lpage>1213</lpage>.<pub-id pub-id-type="pmid">22053108</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0038">
        <mixed-citation publication-type="journal" id="humu22946-cit-0038">
<string-name>
<surname>Sneeringer</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Kuntz</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Knutson</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Pollock</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Richon</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Copeland</surname>
<given-names>RA</given-names>
</string-name>. <year>2010</year>
<article-title>Coordinated activities of wildâtype plus mutant EZH2 drive tumorâassociated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human Bâcell lymphomas</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>107</volume>:<fpage>20980</fpage>â<lpage>20985</lpage>.<pub-id pub-id-type="pmid">21078963</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0039">
        <mixed-citation publication-type="journal" id="humu22946-cit-0039">
<string-name>
<surname>Taal</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>St Pourcain</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Thiering</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>MookâKanamori</surname>
<given-names>DO</given-names>
</string-name>, <string-name>
<surname>Warrington</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Kaakinen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>KreinerâMÃ¸ller</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bradfield</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Freathy</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Geller</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Guxens</surname>
<given-names>M</given-names>
</string-name>, etÂ al. <year>2012</year>
<article-title>Common variants at 12q15 and 12q24 are associated with infant head circumference</article-title>. <source>Nat Genet</source>
<volume>44</volume>:<fpage>532</fpage>â<lpage>538</lpage>.<pub-id pub-id-type="pmid">22504419</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0040">
        <mixed-citation publication-type="journal" id="humu22946-cit-0040">
<string-name>
<surname>Tan</surname>
<given-names>JZ</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>XX</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>HE</given-names>
</string-name>. <year>2014</year>
<article-title>EZH2: biology, disease, and structureâbased drug discovery</article-title>. <source>Acta Pharmacol Sin</source>
<volume>35</volume>:<fpage>161</fpage>â<lpage>174</lpage>.<pub-id pub-id-type="pmid">24362326</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0041">
        <mixed-citation publication-type="journal" id="humu22946-cit-0041">
<string-name>
<surname>TattonâBrown</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hanks</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ruark</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Zachariou</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Duarte S del</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Ramsay</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Snape</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Perdeaux</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Seal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Loveday</surname>, <given-names>C</given-names>
</string-name>, <string-name>
<surname>Banka</surname>
<given-names>S</given-names>
</string-name>, etÂ al. <year>2011</year>
<article-title>Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height</article-title>. <source>Oncotarget</source>
<volume>2</volume>:<fpage>1127</fpage>â<lpage>1133</lpage>.<pub-id pub-id-type="pmid">22190405</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0042">
        <mixed-citation publication-type="journal" id="humu22946-cit-0042">
<string-name>
<surname>TattonâBrown</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hanks</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Douglas</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Banka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bird</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Clericuzio</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>CormierâDaire</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cushing</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Flinter</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Jacquemont</surname>
<given-names>ML</given-names>
</string-name>, etÂ al. <year>2013</year>
<article-title>Weaver syndrome and EZH2 mutations: clarifying the clinical phenotype</article-title>. <source>Am J Med Genet A</source>
<volume>161A</volume>:<fpage>2972</fpage>â<lpage>2980</lpage>.<pub-id pub-id-type="pmid">24214728</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0043">
        <mixed-citation publication-type="journal" id="humu22946-cit-0043">
<string-name>
<surname>TattonâBrown</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Rahman</surname>, <given-names>N.</given-names>
</string-name>
<year>2013</year>
<article-title>The NSD1 and EZH2 overgrowth genes, similarities and differences</article-title>. <source>Am J Med Genet C</source>
<volume>163C</volume>:<fpage>86</fpage>â<lpage>91</lpage>.</mixed-citation>
      </ref>
      <ref id="humu22946-bib-0044">
        <mixed-citation publication-type="journal" id="humu22946-cit-0044">
<collab collab-type="authors">The Cancer Genome Atlas Research Network</collab>
. <year>2013</year>
<article-title>Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</article-title>. <source>N Engl J Med</source>
<volume>368</volume>:<fpage>2059</fpage>â<lpage>2074</lpage>.<pub-id pub-id-type="pmid">23634996</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0045">
        <mixed-citation publication-type="journal" id="humu22946-cit-0045">
<string-name>
<surname>Tomatsu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>MontaÃ±o</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Dung</surname>
<given-names>VC</given-names>
</string-name>, <string-name>
<surname>Grubb</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Sly</surname>
<given-names>WS</given-names>
</string-name>. <year>2009</year>
<article-title>Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome)</article-title>. <source>Hum Mutat</source>
<volume>30</volume>:<fpage>511</fpage>â<lpage>519</lpage>.<pub-id pub-id-type="pmid">19224584</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0046">
        <mixed-citation publication-type="journal" id="humu22946-cit-0046">
<string-name>
<surname>Van Aller</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Pappalardi</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Ott</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Diaz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Brandt</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Dhanak</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>McCabe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Verma</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Creasy</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Tummino</surname>
<given-names>PJ</given-names>
</string-name>, etÂ al. <year>2014</year>
<article-title>Long residence time inhibition of EZH2 in activated polycomb repressive complex 2</article-title>. <source>ACS Chem Biol</source>
<volume>9</volume>:<fpage>622</fpage>â<lpage>629</lpage>.<pub-id pub-id-type="pmid">24304166</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0047">
        <mixed-citation publication-type="journal" id="humu22946-cit-0047">
<string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>IH</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>K</given-names>
</string-name>. <year>2010</year>
<article-title>Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>107</volume>:<fpage>7317</fpage>â<lpage>7322</lpage>.<pub-id pub-id-type="pmid">20368440</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0048">
        <mixed-citation publication-type="journal" id="humu22946-cit-0048">
<string-name>
<surname>Weaver</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>IT</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>DW</given-names>
</string-name>. <year>1974</year>
<article-title>A new overgrowth syndrome with accelerated skeletal maturation, unusual facies, and camptodactyly</article-title>. <source>J Pediatr</source>
<volume>84</volume>:<fpage>547</fpage>â<lpage>552</lpage>.<pub-id pub-id-type="pmid">4366187</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0049">
        <mixed-citation publication-type="journal" id="humu22946-cit-0049">
<string-name>
<surname>Wood</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Esko</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vedantam</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pers</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Gustafsson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Estrada</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Luan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kutalik</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Amin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Buchkovich</surname>
<given-names>ML</given-names>
</string-name>, etÂ al. <year>2014</year>
<article-title>Defining the role of common variation in the genomic and biological architecture of adult human height</article-title>. <source>Nat Genet</source>
<volume>46</volume>:<fpage>1173</fpage>â<lpage>1186</lpage>.<pub-id pub-id-type="pmid">25282103</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0050">
        <mixed-citation publication-type="journal" id="humu22946-cit-0050">
<string-name>
<surname>Xu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>ZJ</given-names>
</string-name>, <string-name>
<surname>Groner</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Cai</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lis</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Stack</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Loda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cato</surname>
<given-names>L</given-names>
</string-name>, etÂ al. <year>2012</year>
<article-title>EZH2 oncogenic activity in castrationâresistant prostate cancer cells is polycombâindependent</article-title>. <source>Science</source>
<volume>338</volume>:<fpage>1465</fpage>â<lpage>1469</lpage>.<pub-id pub-id-type="pmid">23239736</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0051">
        <mixed-citation publication-type="journal" id="humu22946-cit-0051">
<string-name>
<surname>Yap</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Berg</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Schapira</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Moradian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Morin</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Mungall</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Meissner</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Marquez</surname>
<given-names>VE</given-names>
</string-name>, <string-name>
<surname>Marra</surname>
<given-names>MA</given-names>
</string-name>, etÂ al. <year>2011</year>
<article-title>Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation</article-title>. <source>Blood</source>
<volume>117</volume>:<fpage>2451</fpage>â<lpage>2459</lpage>.<pub-id pub-id-type="pmid">21190999</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0052">
        <mixed-citation publication-type="journal" id="humu22946-cit-0052">
<string-name>
<surname>Yasuda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shabbeer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Benson</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Maire</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Burnett</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Desnick</surname>
<given-names>RJ</given-names>
</string-name>. <year>2003</year>
<article-title>Fabry disease: characterization of alphaâgalactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele</article-title>. <source>Hum Mutat</source>
<volume>22</volume>:<fpage>486</fpage>â<lpage>492</lpage>.<pub-id pub-id-type="pmid">14635108</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0053">
        <mixed-citation publication-type="journal" id="humu22946-cit-0053">
<string-name>
<surname>Zaidi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wakimoto</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Overton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>RomanoâAdesman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bjornson</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Breitbart</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Carriero</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Cheung</surname>, <given-names>YH</given-names>
</string-name>, etÂ al. <year>2013</year>
<article-title>De novo mutations in histoneâmodifying genes in congenital heart disease</article-title>. <source>Nature</source>
<volume>498</volume>:<fpage>220</fpage>â<lpage>223</lpage>.<pub-id pub-id-type="pmid">23665959</pub-id></mixed-citation>
      </ref>
      <ref id="humu22946-bib-0054">
        <mixed-citation publication-type="journal" id="humu22946-cit-0054">
<string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Holmfeldt</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Heatley</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>PayneâTurner</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Easton</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rusch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>SC</given-names>
</string-name>, etÂ al. <year>2012</year>
<article-title>The genetic basis of early Tâcell precursor acute lymphoblastic leukaemia</article-title>. <source>Nature</source>
<volume>481</volume>:<fpage>157</fpage>â<lpage>163</lpage>.<pub-id pub-id-type="pmid">22237106</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>